These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 24356998)

  • 1. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
    Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
    J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
    Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
    Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HtrA1 Down-regulation Induces Cisplatin Resistance in Colon Cancer by Increasing XIAP and Activating PI3K/Akt Pathway.
    Xiong Z; Fu Z; Shi J; Jiang X; Wan H
    Ann Clin Lab Sci; 2017 May; 47(3):264-270. PubMed ID: 28667026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
    Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
    Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
    Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway.
    Wang H; Zhang G; Zhang H; Zhang F; Zhou B; Ning F; Wang HS; Cai SH; Du J
    Eur J Pharmacol; 2014 Jan; 723():156-66. PubMed ID: 24333218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway].
    Qi Z; Wang Y; Zhou X
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1290-3. PubMed ID: 22985566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway.
    Yu M; Qi B; Xiaoxiang W; Xu J; Liu X
    Biomed Pharmacother; 2017 Jun; 90():677-685. PubMed ID: 28415048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MTA1 overexpression induces cisplatin resistance in nasopharyngeal carcinoma by promoting cancer stem cells properties.
    Feng X; Zhang Q; Xia S; Xia B; Zhang Y; Deng X; Su W; Huang J
    Mol Cells; 2014 Sep; 37(9):699-704. PubMed ID: 25245523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
    Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Lu XX; Cao LY; Chen X; Xiao J; Zou Y; Chen Q
    Biomed Res Int; 2016; 2016():2476842. PubMed ID: 27822469
    [No Abstract]   [Full Text] [Related]  

  • 14. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
    Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
    Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
    Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
    Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cx43 reverses the resistance of A549 lung adenocarcinoma cells to cisplatin by inhibiting EMT.
    Yu M; Zhang C; Li L; Dong S; Zhang N; Tong X
    Oncol Rep; 2014 Jun; 31(6):2751-8. PubMed ID: 24789679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
    Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
    Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells].
    Zhang MC; Hu CP; Chen Q
    Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):408-12. PubMed ID: 17152483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
    Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.